Skip to main content

08-02-2023 | Heart failure | News

Meta-analysis shows mixed picture for GLP-1 receptor agonists in heart failure

Author: Eleanor McDermid


medwireNews: A meta-analysis suggests that glucagon-like peptide (GLP)-1 receptor agonists may help prevent new-onset heart failure in people with type 2 diabetes.

However, in people with preexisting heart failure, GLP-1 receptor agonist treatment did not reduce the risk for acute heart failure events or mortality.

The meta-analysis, which is published in Diabetes, Obesity and Metabolism, included 54,092 participants of seven randomized controlled trials of GLP-1 receptor agonists in people with type 2 diabetes, 16% of whom had a history of heart failure.

Among those without preexisting heart failure, being assigned to GLP-1 receptor agonist treatment was associated with a significant 16% reduction in the risk for the composite outcome of heart failure hospitalization or cardiovascular death.

This was driven mainly by a 15% reduction in the risk for cardiovascular death, and there was also a 15% reduced risk for all-cause death. The risk for heart failure hospitalization was reduced by a nonsignificant 19%.

By contrast, none of these outcomes were influenced by treatment allocation in participants with a history of heart failure. However, GLP-1 receptor agonist treatment significantly reduced the risk for major adverse cardiovascular events regardless of whether the participants had heart failure, with 15% and 12% reductions in those with and without a history of heart failure, respectively.

But João Pedro Ferreira (University of Porto, Portugal) and co-researchers stress that the treatment benefits and risks of GLP-1 receptor agonists are less clear in people who have advanced heart failure, recent acute heart failure events, or a severely reduced ejection fraction – subgroups that were not included in the analyzed clinical trials.

Indeed, they point to smaller studies suggesting that GLP-1 receptor agonists may be associated with an increased risk for serious cardiac events, particularly arrhythmias, in this subgroup.

And the team stresses the demonstrated protective effects of sodium-glucose cotransporter 2 inhibitors against heart failure events irrespective of whether people have the condition at baseline.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2023 Springer Healthcare Ltd, part of the Springer Nature Group

Diabetes Obes Metab 2023; doi:10.1111/dom.14997


Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »